-- メダリオン・メタルズ(ASX:MM8)は、西オーストラリア州のフォレスタニア金プロジェクトにおいて、コズミック・ボーイ選鉱プラントの改修を通じて金生産を前倒しする取り組みを進めていると、金曜日にオーストラリア証券取引所に提出した書類で明らかにした。 同社によると、同プラントで短期間のうちに金選鉱能力を確立することで、メダリオン鉱区内の金鉱床の商業化が可能となり、第三者からの鉱石供給による収益源も確保できるという。 また、コズミック・ボーイ選鉱プラントの改修計画と並行して、レイブンソープ鉱石の生産にも最小限の影響で金生産の機会を創出できると付け加えた。 メダリオン・メタルズのポール・ベネット社長は、「重要なのは、この計画が成功すれば、レイブンソープ鉱石の納入に先立ち、選鉱インフラのリスクを軽減しながら収益を前倒しできる可能性があるということだ」と述べた。 同社の株価は、金曜日の取引で5%上昇した。
Related Articles
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%